Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Trial
Official title:
The Effect of Prone Positioning on Lung Aeration and Ventilation-perfusion Matching in Mechanically Ventilated Patients With Coronavirus Disease Related Acute Respiratory Distress Syndrome
The consensus therapeutic strategy implies that COVID patients with acute lung injury due to coronavirus are routinely placed in prone position in an attempt to improve oxygenation by increasing ventilation homogeneity. The purpose of the study is to quantify with the electrical impedance tomography (EIT) the changes in the ventilation and aeration in the dorsal regions of the lung when the patient is placed in prone position.
Patients with acute respiratory distress syndrome (ARDS) frequently develop atelectasis in dorsal lung regions because of gravity and the compression by the heart and the diaphragm. Since lung perfusion is predominantly distributed in lower lung regions, a reduction of ventilation in these areas results in further ventilation-perfusion mismatch, called shunt. The development of atelectatic lung regions necessitate the use of higher ventilation pressures, which in turn results in excessive transpulmonary pressures and ventilation-induced lung injury in the ventral regions. Therefore it is common to promote the prone position in patients with ARDS in order to improve ventilation-perfusion matching and thus, protect the ventral regions from hyperinflation. In patients with COVID-19-related ARDS, the value of such therapeutic strategy based on placing in prone position has not been completely elucidated. The aims of the study are to determine whether prone positioning improves dorsal regional ventilation when compared to supine position. Moreover, another aim is to assess the changes in intrapulmonary shunt following patient position changes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05543616 -
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04516811 -
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
|
Phase 3 | |
| Completed |
NCT04334044 -
Treatment of SARS Caused by COVID-19 With Ruxolitinib
|
Phase 1/Phase 2 | |
| Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
| Recruiting |
NCT04466241 -
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT04381923 -
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia
|
N/A | |
| Recruiting |
NCT04402879 -
CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals
|
N/A | |
| Recruiting |
NCT04661631 -
Surgery and Lung Ultrasound in COVID-19 Infection
|
||
| Completed |
NCT04376476 -
Host-pathogen Interactions During SARS-CoV-2 Infection
|
N/A | |
| Completed |
NCT04375098 -
Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection
|
Phase 2 | |
| Completed |
NCT04402060 -
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04354779 -
Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
|
||
| Recruiting |
NCT04367207 -
African Covid-19 Critical Care Outcomes Study
|
||
| Terminated |
NCT04409873 -
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
|
Phase 2 | |
| Completed |
NCT04602351 -
Communication in ICU During COVID-19
|
||
| Terminated |
NCT04707703 -
Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
|
Phase 3 | |
| Active, not recruiting |
NCT04987528 -
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
|
||
| Completed |
NCT04667936 -
Evaluation of Sedation in COVID-19 ARDS
|
||
| Completed |
NCT04423770 -
COVID-19 Related Health and Infection Control Practices Among Dentists
|